Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy.
BACKGROUND
We previously showed that chronic administration of an angiotensin converting enzyme (ACE) inhibitor to rats with passive Heymann nephritis (PHN), a model of membranous nephropathy with proteinuria and increased renal synthesis of endothelin-1 (ET-1), reduces urinary proteins and partially limits the exaggerated ET-1 renal synthesis. Here we compared the effect of an ETA receptor antagonist and an ACE-inhibitor given as single therapies with a combination of the two drugs in uninephrectomized PHN rats.


METHODS
PHN was induced with a single i.v. injection of rabbit anti-Fx1A antibody in 40 male Sprague Dawley rats. To accelerate the onset of renal damage rats underwent uninephrectomy seven days later and were subsequently treated until eight months with the ETA receptor antagonist LU-135252 (50 mg/kg b.i.d. p.o.) or the ACE-inhibitor trandolapril (1 mg/kg in the drinking water) or the combination of the two drugs.


RESULTS
Either LU-135252 or trandolapril given alone prevented the increase in systolic blood pressure (SBP). Combined therapy was even more effective than single drugs. While LU-135252 and trandolapril reduced proteinuria by 23 to 25%, the drug combination resulted in 45% lowering of urinary proteins. Serum creatinine was significantly decreased by the combination, but not by the single drugs. Glomerulosclerosis and tubulointerstitial damage were more reduced by combined therapy than by LU-135252 or trandolapril alone.


CONCLUSIONS
These data suggest that contemporary blocking angiotensin II (Ang II) and ET-1 in an accelerated model of PHN had an additive renoprotective effect than single blocking Ang II or ET-1 and would represent a therapeutic advantage for renal disease patients who do not completely respond to ACE inhibitors.
Mario Negri Institute for Pharmacological Research, Ospedali Riuniti di Bergamo, Italy.
A
A
Benigni
D
D
Corna
R
R
Maffi
G
G
Benedetti
C
C
Zoja
G
G
Remuzzi
D000804:Angiotensin II / Q000037:antagonists & inhibitors* / Q000502:physiology; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D019332:Endothelin-1 / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000502:physiology; D005921:Glomerulonephritis / Q000188:drug therapy*; D007211:Indoles / Q000627:therapeutic use*; D007668:Kidney / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D008297:Male; D010666:Phenylpropionates / Q000627:therapeutic use*; D011507:Proteinuria / Q000188:drug therapy; D011743:Pyrimidines / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley
D019332:Endothelin-1; D007211:Indoles; D010666:Phenylpropionates; D011743:Pyrimidines; D000804:Angiotensin II; C052035:trandolapril; C107831:darusentan